Project description DEENESFRITPL Identification of predictive biomarkers for cancer immunotherapy Despite recent impressive advances in cancer immunotherapy, the majority of cancer patients do not respond to any of the available immunotherapeutics. Therefore, there is an urgent need for reliable biomarkers able to identify patients that would benefit from this treatment option. The EU-funded GlyCANswer project aims to elucidate how the cancer glycoproteome dictates the immune response to facilitate the development of new strategies for immunotherapy and to identify predictive biomarkers for treatment response. The project's objective is to uncover the interplay between the cancer cell glycoproteome and immune recognition in lung and breast cancer, using a combination of glycoproteomics, glycomics and immune profiling approaches in mouse models and cell culture systems. Show the project objective Hide the project objective Objective Cancer continues to be the most formidable challenge in modern medicine and the second leading cause of deaths worldwide. However, in recent years, the treatment of unresectable cancer has undergone a paradigm shift with the advent of immunotherapy. Yet, despite the great progress in the field, the majority of cancer patients still do not respond to any of the available immunotherapeutics and no reliable biomarker exists to predict those patients that would benefit from it.In order to facilitate the development of new strategies for immunotherapy, and to identify improved predictive biomarkers for treatment response, the GlyCANswer project envisions to elucidate how the cancer glycoproteome dictates the immune response. The GlyCANswer project aims to unravel the interplay between the cancer cell glycoproteome and immune recognition in the two most frequent malignancies worldwide, namely lung and breast cancer. By using a combination of cutting-edge glycoproteomics, glycomics and immune profiling approaches in innovative mouse models and cell culture systems, the GlyCANswer project will 1) map the immunomodulatory glycosylation of cancer cells 2) explore the detailed mechanisms of glycan-mediated immune regulation 3) identify new biomarkers and provide new therapeutic targets for immune therapy. Fields of science medical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2018 - Individual Fellowships Call for proposal H2020-MSCA-IF-2018 See other projects for this call Funding Scheme MSCA-IF-EF-SE - Society and Enterprise panel Coordinator INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH Net EU contribution € 174 167,04 Address DR BOHRGASSE 3 1030 Wien Austria See on map Region Ostösterreich Wien Wien Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 174 167,04
